These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31586799)

  • 41. Cognitive processing speed deficits in multiple sclerosis: Dissociating sensorial and motor processing changes from cognitive processing speed.
    Clough M; Dobbing J; Stankovich J; Ternes A; Kolbe S; White OB; Fielding J
    Mult Scler Relat Disord; 2020 Feb; 38():101522. PubMed ID: 31785491
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A preliminary validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) tool in an Irish population with multiple sclerosis (MS).
    O'Connell K; Langdon D; Tubridy N; Hutchinson M; McGuigan C
    Mult Scler Relat Disord; 2015 Nov; 4(6):521-5. PubMed ID: 26590658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Associations Between Findings From Myelin Water Imaging and Cognitive Performance Among Individuals With Multiple Sclerosis.
    Abel S; Vavasour I; Lee LE; Johnson P; Ristow S; Ackermans N; Chan J; Cross H; Laule C; Dvorak A; Schabas A; Hernández-Torres E; Tam R; Kuan AJ; Morrow SA; Wilken J; Rauscher A; Bhan V; Sayao AL; Devonshire V; Li DKB; Carruthers R; Traboulsee A; Kolind SH
    JAMA Netw Open; 2020 Sep; 3(9):e2014220. PubMed ID: 32990740
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structural and cognitive correlates of fatigue in progressive multiple sclerosis.
    Andreasen AK; Iversen P; Marstrand L; Siersma V; Siebner HR; Sellebjerg F
    Neurol Res; 2019 Feb; 41(2):168-176. PubMed ID: 30513278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.
    Papadopoulou A; Müller-Lenke N; Naegelin Y; Kalt G; Bendfeldt K; Kuster P; Stoecklin M; Gass A; Sprenger T; Radue EW; Kappos L; Penner IK
    Mult Scler; 2013 Sep; 19(10):1290-6. PubMed ID: 23459568
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cognitive trajectories in relapsing-remitting multiple sclerosis: Evidence of multiple evolutionary trends.
    London F; De Haan A; Benyahia Z; Landenne G; Duprez T; van Pesch V; El Sankari S
    Mult Scler Relat Disord; 2023 Sep; 77():104848. PubMed ID: 37390678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitive Performance in Relapsing-Remitting Multiple Sclerosis: At Risk or Impaired?
    Altieri M; Fratino M; Maestrini I; Dionisi C; Annecca R; Vicenzini E; Di Piero V
    Dement Geriatr Cogn Disord; 2020; 49(6):539-543. PubMed ID: 33735893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis.
    Saposnik G; Andhavarapu S; Sainz de la Maza S; Castillo-Triviño T; Borges M; Barón BP; Sotoca J; Alonso A; Caminero AB; Borrega L; Sánchez-Menoyo JL; Barrero-Hernández FJ; Calles C; Brieva L; Blasco MR; García-Soto JD; Del Campo-Amigo M; Navarro-Cantó L; Agüera E; Garcés M; Carmona O; Gabaldón-Torres L; Forero L; Hervás M; García-Arcelay E; Terzaghi M; Gómez-Ballesteros R; Maurino J
    Mult Scler Relat Disord; 2022 Dec; 68():104138. PubMed ID: 36029707
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis.
    Yalachkov Y; Soydaş D; Bergmann J; Frisch S; Behrens M; Foerch C; Gehrig J
    Mult Scler Relat Disord; 2019 May; 30():33-37. PubMed ID: 30735970
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diabetes and anxiety adversely affect cognition in multiple sclerosis.
    Marrie RA; Patel R; Figley CR; Kornelsen J; Bolton JM; Graff L; Mazerolle EL; Marriott JJ; Bernstein CN; Fisk JD;
    Mult Scler Relat Disord; 2019 Jan; 27():164-170. PubMed ID: 30384203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
    Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
    Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A longitudinal study of cognitive function in multiple sclerosis: is decline inevitable?
    Katsari M; Kasselimis DS; Giogkaraki E; Breza M; Evangelopoulos ME; Anagnostouli M; Andreadou E; Kilidireas C; Hotary A; Zalonis I; Koutsis G; Potagas C
    J Neurol; 2020 May; 267(5):1464-1475. PubMed ID: 32008073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T
    Louapre C; Govindarajan ST; Giannì C; Madigan N; Nielsen AS; Sloane JA; Kinkel RP; Mainero C
    Neuroimage Clin; 2016; 12():879-886. PubMed ID: 27872810
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recovery of cognitive function after relapse in multiple sclerosis.
    Benedict RH; Pol J; Yasin F; Hojnacki D; Kolb C; Eckert S; Tacca B; Drake A; Wojcik C; Morrow SA; Jakimovski D; Fuchs TA; Dwyer MG; Zivadinov R; Weinstock-Guttman B
    Mult Scler; 2021 Jan; 27(1):71-78. PubMed ID: 31971066
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of sexual function in women at two stages of multiple sclerosis.
    Firdolas F; Ozan T; Onur R; Bulut S; Orhan I
    World J Urol; 2013 Aug; 31(4):929-33. PubMed ID: 22669360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment.
    Megna R; Alfano B; Lanzillo R; Costabile T; Comerci M; Vacca G; Carotenuto A; Moccia M; Servillo G; Prinster A; Brescia Morra V; Quarantelli M
    J Neurol; 2019 Feb; 266(2):361-368. PubMed ID: 30498912
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.
    Zivadinov R; Sepcic J; Nasuelli D; De Masi R; Bragadin LM; Tommasi MA; Zambito-Marsala S; Moretti R; Bratina A; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
    J Neurol Neurosurg Psychiatry; 2001 Jun; 70(6):773-80. PubMed ID: 11385012
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum Tumor Necrosis Factor-Alpha Levels Correlate with Cognitive Function Scales Scores in Multiple Sclerosis Patients.
    El-Salem K; Al-Mistarehi AH; Hanan Khalil ; Alham Al-Sharman ; Yassin A
    Mult Scler Relat Disord; 2021 Jan; 47():102621. PubMed ID: 33197871
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Cambridge Neuropsychological Test Automated Battery (CANTAB) Versus the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) for the Assessment of Cognitive Function in Patients with Multiple Sclerosis.
    Talebi M; Majdi A; Kamari F; Sadigh-Eteghad S
    Mult Scler Relat Disord; 2020 Aug; 43():102172. PubMed ID: 32442887
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis.
    Planche V; Gibelin M; Cregut D; Pereira B; Clavelou P
    Eur J Neurol; 2016 Feb; 23(2):282-9. PubMed ID: 25903918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.